PG, JNJ, and KO Look Boring-Until Their 2027 Re-Rating Hits

Why these defensive names still matter

Defensive does not mean stagnant. It means the underlying business is still running while the market fixates on newer narratives. That is why this group still deserves attention. JNJ has raised guidance and says it is on track to exceed $100 billion in annual revenue; KO just posted 5% global unit case volume growth with a 34.9% operating margin; and PG remains a reset story, with Q4 net sales +2%, organic sales 0%, and diluted EPS down 15%. If products keep moving and margins hold, these stocks can still surprise.

The bull and bear split

The bullish case is straightforward: these are established franchises showing real operating activity. JNJ is not only talking about scale; it already posted Q1 sales of $24.1 billion and has a December 8, 2026 enterprise business review that could give investors a cleaner view of the portfolio. KO's margin profile shows this is still a high-quality business. PG is the real debate: is management's cleanup phase a smart reset, or just slow growth in disguise, especially after revenue fell short of expectations?

Why the setup matters now

The opening exists before the next round of confirmations. JNJ's December review could sharpen the market's view quickly. KO already has a setup investors tend to like: global unit case volume grew 5%, and management is guiding to organic revenue growth of 4% to 5%. PG is different. It is still in the prove-it phase after flat organic sales in both Q4 and its more recent second quarter. That makes it the highest risk-reward name in the group: better execution could be rewarded quickly, while continued hesitation would keep the stock in holding-pattern mode.

Johnson & Johnson: the defensive story is shifting toward operating recovery

JNJ is the name where the old defensive thesis may be giving way to a more direct operating recovery story. After Q2 reported sales of $25,310 million and 6.6% reported sales growth, the company is guiding to estimated reported sales of $101.1 billion for 2026 at the midpoint. The important change is not just that guidance had already improved from Q1; it is that management raised the full-year outlook after another strong quarter. That suggests the revenue engine is doing more than holding the line.

What is improving

JNJ's momentum is showing up across consecutive quarters. Investors already saw Q1 sales of $24.1 billion, and Q2 came in higher at $25.31 billion. For a company of this size, that kind of steady top-line progress matters because it can change how the market reads future earnings volatility.

The portfolio argument also looks stronger. Management highlighted approvals and updates around TREMFYA, CAPLYTA, and the Dual Energy THERMOCOOL SMARTTOUCH SF platform, following earlier developments such as ICOTYDE and updates around TECVAYLI plus DARZALEX FASPRO. That breadth matters: this is not a company relying on a single product to carry the story.

Why December could matter

That is why the December 8, 2026 enterprise business review matters. For a complex company like JNJ, a dedicated review could help investors separate the operating units that are working from the ones still weighing on sentiment. If management presents a clearer roadmap while the sales trajectory remains intact, the stock could start attracting recovery and quality multiples rather than just a safety premium.

The bear case is simple enough: Q2 net earnings of $5,534 million were essentially flat, and diluted EPS slipped 0.9%. But that is the debate, not the conclusion. If December reinforces the top-line story, investors may treat those headline earnings pressures as temporary noise.

Coca-Cola: brand strength is still showing up in volume and margin

Coca-Cola is the easiest name to evaluate because the numbers speak plainly. Global unit case volume grew 5%, which is the kind of result that shows the brands still have real shelf pull. A 2027 re-rating does not require a new narrative; it mainly requires the market to stop treating Coke like a sleepy staple and start paying for a business that keeps converting brand loyalty into volume and profit.

Why the numbers matter

The appeal is not just that people are buying the product. It is that demand is still translating into dollars. Last quarter, operating margin was 34.9%. Combined with full-year comparable earnings per share growth of 8% to 9% and organic revenue growth of 4% to 5%, the setup looks sturdier than the stock's image suggests.

That distinction matters for 2027. If consumers keep accepting the pricing and the margin holds, investors can start viewing Coke more as a quality compounder than a routine defensive holding.

The main caveat is that this is not a hidden story. The stock has already climbed more than 19% this year, so investors are not getting in unnoticed. Still, Coke does not need to be cheap to work; it just needs the same consumer traction and margin discipline to continue. The peer backdrop also helps: PepsiCo's North American beverage volume fell 4% in the second quarter.

What to watch into next year

• Global unit case volume grew 5% and should stay meaningfully positive.
• The 34.9% operating margin should remain the benchmark for pricing power.
• Full-year comparable earnings per share growth of 8% to 9% needs to hold.
• The Fairlife production stoppage should stay immaterial, as management said.

Procter & Gamble: the upside case depends on execution improving

PG is the reset name in this group, which is also why it has the most room to surprise.

Why lower expectations can help

Management has described fiscal 2026 as a "foundation building" year. That may sound unexciting, but it is useful framing. It tells investors they are watching a cleanup phase, not a fully resolved growth story. In that context, the market does not need a miracle. It needs evidence that the reset is starting to stick.

The recent quarters show why the setup still exists. PG delivered Q4 net sales +2%, but organic sales were 0% and diluted EPS fell 15%. That suggests the brands still moved product, but consumer response was soft and earnings leverage lagged. The more recent second quarter looked similar in the key area: organic sales were unchanged, while core EPS was in-line. That is not a collapse. It is a messy middle, and messy middles can re-rate faster than expected if execution begins to improve.

What has to change

The bull case is straightforward: better execution, with management following through on its pledge to put the consumer first. The bear case is just as clear. Last month, revenue missed again at $21.2 billion vs. $21.38 billion expected, and shoppers have become more value conscious, which can boost private-label competition.

The main invalidation is also simple: if PG keeps posting flat organic sales or another revenue miss, this remains a holding pattern rather than a re-rating story.